Meissa Vaccines, Inc.

29 articles with Meissa Vaccines, Inc.

• Meissa Vaccines Announces Positive Interim Clinical Data for Its Intranasal Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine Candidate for Infants

  11/7/2022

  Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced interim clinical data of MV-012-968, Meissa’s intranasal live attenuated RSV vaccine candidate, from a Phase 1c study in RSV-naïve (seronegative) infants and young children.

• 

  Nasal Spray Vaccines for COVID-19: a Viable Option or Too Little, Too Late?

  7/27/2022

  SARS-CoV-2 typically enters the body via the nose or mouth. Because of this, many think a nasal spray vaccine would do a better job of preventing COVID-19 infection and cutting transmission than an injection.

• Meissa Vaccines Presented at The White House Summit on the Future of COVID-19 Vaccines

  7/27/2022

  Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced that Martin Moore, Ph.D., cofounder and Chief Scientific Officer of Meissa, spoke on a panel entitled, “Innovation in Vaccine Delivery,” at the Summit on the Future of COVID-19 Vaccines hosted by The White House Office for COVID-19 Response.

• Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

  7/11/2022

  Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development.

• 

  Is the US Running Blind Toward COVID-19 Boosters?

  4/26/2022

  How many boosters are enough to protect against COVID-19 infection? This question has been at the forefront of the minds of everyone as news crops up about yearly boosters.
• 

  Intranasal, Bivalent Vaccines on the Horizon to Defeat Number 3 Killer COVID-19

  4/25/2022

  With COVID-19 still very much a threat to the public, researchers are working on developing new treatments. Read on for more updates.

• Meissa Appoints Drs. Dan H. Barouch and Mark J. Mulligan to Scientific Advisory Board

  12/16/2021

  Meissa Vaccines today announced the appointments of Dan H. Barouch, M.D., Ph.D., and Mark J. Mulligan, M.D., FIDSA, to the Company’s Scientific Advisory Board.

• 

  COVID-19 is a Sprint AND a Marathon, Requiring New and Better Vaccines

  11/4/2021

  While some may wonder about the commercial future of these late-to-the-market solutions, the developers themselves are taking a long view.

• Meissa Announces Positive Preliminary Clinical Data on Safety and Immunogenicity of Intranasal COVID-19 Vaccine

  10/28/2021

  Meissa announced today positive preliminary data from the interim analysis of 49 patients in a Phase 1 clinical study of MV-014-212, the company’s intranasal recombinant live attenuated COVID-19 vaccine (ClinicalTrials.gov Identifier: NCT04798001).

• 

  BioSpace Movers & Shakers, Aug. 6

  8/6/2021

  Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers.

• Meissa Appoints Robert Walker, M.D., Chief Medical Officer

  8/3/2021

  Meissa Vaccines announced today the appointment of Robert Walker, M.D., as Chief Medical Officer.

• 

  Meissa's Intranasal COVID-19 Vaccine Shows Promise in Non-Human Primates

  7/19/2021

  Meissa’s intranasal vaccine for COVID-19 equals the protection afforded by existing vaccines in the same class of subjects after only a single dose, according to data presented this week at the American Society of Virology annual meeting.

• Meissa Vaccines Begins Study of RSV Vaccine Candidate in Seronegative Children

  6/30/2021

  Meissa Vaccines announced today the first seronegative participants have received MV-012-968, Meissa’s intranasal live attenuated RSV vaccine candidate, in a Phase 1c study in infants and young children.

• 

  Meissa’s Nasal COVID-19 Vaccine Uses Codon Deoptimization for Stronger Responses

  3/25/2021

  Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants) recently was cleared for Phase I trials, which will start at the end of March.

• Meissa Announces First Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV

  1/21/2021

  The randomized, double-blind, placebo-controlled challenge study is designed to evaluate safety and prophylactic efficacy of MV-012-968 against symptomatic respiratory syncytial virus (RSV)

• 

  BioSpace Movers & Shakers, Oct. 16

  10/16/2020

  Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.

• Meissa Vaccines Expands Leadership Team as Company Advances Intranasal RSV and COVID-19 Live Attenuated Vaccine Candidates

  10/14/2020

  Vaccine manufacturing and regulatory expert and business development and strategy leader bring further expertise as company advances RSV vaccine candidate into Phase 2 and scales production of an intranasal COVID-19 vaccine candidate for clinical trials REDWOOD CITY, Calif.--( BUSINESS WIRE )-- Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today the appointments of William

• 

  Biopharma Update on the Novel Coronavirus: July 20

  7/20/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 20, 2020.
• 

  Another COVID-19 Vaccine Joins the Race – This Time, it’s a Live, Weakened Virus

  7/20/2020

  Another COVID-19 vaccine candidate recently entered the races. The difference – this one is a live attenuated (weakened) virus expressing the coronavirus’s signature spike protein on its surface. And it’s delivered nasally, not a shot.

• Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV

  6/30/2020

  Meissa’s COVID-19 vaccine candidate, MV-014-210, is designed to be delivered as a single, intranasal, adjuvant-free dose, that is economical and can be rapidly scaled to supply global demands Preliminary clinical data show MV-012-968, the company’s vaccine candidate for respiratory syncytial virus, is heavily attenuated and induces a RSV-specific mucosal IgA response in the majority of healthy adult, seropositive recipients SOUTH SAN FRANCIS